CoChat

ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism

Open access
Centanni, Marco, Duntas, Leonidas, Feldt-Rasmussen, Ulla, Koehrle, Josef, Peeters, Robin P, Razvi, Salman, Trimboli, Pierpaolo, Virili, Camilla · 2025 · European Thyroid Journal

The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index; 91 of the 188 sources its claims cite were checked for support.

Abstract

Sodium levothyroxine (LT4) as a monotherapy represents the mainstay of treatment of hypothyroidism, and its use has increased over time. Nevertheless, it faces several potential barriers in its ‘real life’ utilization, and hence its clinical effectiveness may be marred. This is suggested by the frequent situation of patients failing to reach the therapeutic goals of symptom relief and serum TSH control. Thus, an expert task force was approved by the Guidelines Board of the European Thyroid Association to examine the available data and to formulate recommendations based on the available evidence and the experts’ deduction. The task force provides a body of suggestions to optimize the levothyroxine treatment in monotherapy, considering the key point in the individualization of treatment. Furthermore, the nutritional, pharmacological and pathological factors, potentially leading to the increased need for levothyroxine, are discussed, with a specific focus on the use of liquid and softgel formulations of the hormone.

Overview

CoChat Summary

TL;DR

This ETA guideline provides recommendations to optimize levothyroxine sodium monotherapy in hypothyroidism, emphasizing individualized treatment and management of adherence, nutritional, pharmacological, and pathological interferences. It highlights liquid and softgel LT4 formulations for patients at risk of tablet malabsorption or altered gastric pH.

Key findings

  • Almost half of LT4-treated primary hypothyroid patients worldwide appear under- or over-treated when serum TSH is used as the marker of adequate thyroid hormone status.
  • In a cited absorption study, a free T4 increment at 3 h above 5.15 pmol/L had 97% sensitivity and 80% specificity for excluding true malabsorption.
  • Coffee co-administration decreased the incremental rise in serum T4 by 36% in hypothyroid patients and 29% in healthy volunteers, and decreased peak T4 by 30% and 19%, respectively, while delaying T4 maximum serum level by 38 and 43 min.
  • A cited meta-analysis found that switching from tablet to liquid LT4 produced a pooled mean TSH reduction of 4.23 mU/L (95% CI 3.69–4.77); the guideline also reports increased LT4 needs in celiac disease (+49%), lactose intolerance (median ~31% higher), ulcerative colitis (26% higher in 12/13 patients), and RYGB (+27%).

Methods

  • An expert task force approved by the ETA Guidelines Board examined available data and formulated recommendations based on available evidence and expert deduction; the methodology is provided as Supplementary Material.
  • Recommendations are graded by strength, quality of evidence using Ø symbols, and agreement votes, mostly 8/8.
  • The paper is a narrative guideline synthesis covering LT4 pharmacology, adherence, timing, food and drug interactions, comorbidities, special populations, and tablet versus liquid/softgel formulations.

Limitations

  • The paper states that special-situation statements are mainly expert opinion based due to limited peer-reviewed publications; it also notes no focused RCTs in elderly patients, no controlled trials for fertility-treatment clinical outcomes, sparse RCTs comparing formulations, and no prospective studies systematically comparing liquid gel with solid formulations for clinical outcomes.
  • The paper states that most formulation-comparison studies were small, short, non-comparable, and at high risk of selection and performance bias.
  • Evident from the text: many recommendations are weak or based on low-quality evidence, and several authors report industry ties (speaker honoraria, speaker fees, or consulting for Merck, Abbott, Berlin-Chemie, and Institut Biochimique SA), although the guideline itself received no specific funding.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1530/etj-25-0123

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

75 Valid · 3 Not valid · 67 Not checked · 13 Own results and interpretations

104 more claims · 52 with their cited sources checked

Create a free account to see all 158 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 8
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 132 references

Research works printed but not linked: 2

  1. Feldt-Rasmussen, 2020, Endotext [Internet]
  2. Feldt-Rasmussen, 2020, Laboratory measurement of thyroid-related hormones, proteins, and autoantibodies in serum, 868

Cited by

See all 38

Metadata

Authors
Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C.
Affiliations
  • Sapienza University of Rome (IT)
  • National and Kapodistrian University of Athens (GR)
  • Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital 3 , ,
  • Institut für Experimentelle Endokrinologie, Charité Universitätsmedizin Berlin 4 , ,
  • Erasmus MC (NL)
  • Centre for Life (GB)
  • Ente Ospedaliero Cantonale (CH)
Corresponding author
Centanni, Marco
Venue
European Thyroid Journal
Published
2025-07-07
Volume
14
Issue
4
ISSN
  • 2235-0640 (ISSN-L)
  • 2235-0802
OpenAlex
W4412070283
Cited by
38
References
132
Citations by year
2026: 32 · 2025: 6
FWCI
25.72
Type
journal article
Language
en
Open access
Locations
  • European Thyroid Journal (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
levothyroxine, hypothyroidism, monotherapy, personalized treatment, treatment optimization, barriers to treatment adherence, dietary factors, pharmacological factors, pathological factors
MeSH terms
Humans, Hypothyroidism, Thyrotropin, Thyroxine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism. https://app.cochat.ai/papers/10.1530/etj-25-0123
The paper
Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C. (2025). ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism. European Thyroid Journal. https://doi.org/10.1530/etj-25-0123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.